GIPC1 and ovarian carcinoma: The chemiluminescent optical fiber immunosensor detected 77% and 54% anti-GIPC-1 AAbs positive sera within breast and ovarian carcinoma patients, respectively, as compared to ELISA, which only detected 27% and 18%, respectively [37].